Introduction
With ageing of the world's population, the prevalence of dementia increases: 46.8 million people worldwide were living with dementia in 2015. This is projected to reach 74.7 million in 2030 and 131.5 million in 2050, with 60% suffering from Alzheimer's disease (AD). 1 In Hong Kong, the prevalence of mild dementia has been reported to be 8.9% for adults aged 70 years or over, with 64.6% suffering from AD. 2 
Appropriate
New knowledge added by this study • Positron emission tomography (PET) with or without Pittsburgh compound B (PIB) brain imaging helps improve the accuracy of dementia subtype diagnosis in Chinese patients.
Implications for clinical practice or policy
• PET with or without PIB brain imaging should be considered in patients with dementia who attend the memory clinic, especially if there is diagnostic difficulty.
management of demented patients begins with correct diagnosis of dementia subtype that allows earlier implementation of disease-specific treatment.
In particular, cholinesterase inhibitors (ChEIs) or Nmethyl-D-aspartate receptor antagonists are mostly suitable for the treatment of AD. The current clinical diagnostic guidelines for various types of dementia have limited sensitivities and specificities, however. The sensitivity and specificity of clinical diagnostic ORIGINAL ARTICLE and mixed dementia, respectively. The agreement between the initial and final post-imaging dementia subtype diagnosis was only fair, with a Cohen's kappa of 0.25 (95% confidence interval, 0.05-0.45). For the 21 subjects who underwent 11 C-PIB PET imaging, 19% (n=4) of those with Alzheimer's disease (PIB positive) were initially diagnosed with nonAlzheimer's disease dementia.
Conclusions:
In this study, PET with or without 11 C-PIB brain imaging helped improve the accuracy of diagnosis of dementia subtype in 36% of our patients with underlying Alzheimer's disease, dementia with Lewy bodies, vascular dementia, and frontotemporal dementia. criteria for AD, dementia with Lewy bodies (DLB), and frontotemporal dementia (FTD) have been reported as 81% and 70%, 50% and 80%, 85% and 95%, respectively. [3] [4] [5] [6] In the most recent diagnostic criteria for AD, additional use of biomarkers of AD has been recommended by the National Institute on Aging and Alzheimer's Association to improve the accuracy of AD diagnosis. 3 Biomarkers for the diagnosis of AD include cerebrospinal fluid (CSF), amyloid pathological imaging (eg carbon 11-labelled Pittsburgh compound B [ -FDG] PET) that yield sensitivities and specificities of at least 90% and 85%, respectively in the diagnosis of AD, DLB, and FTD. 3, [7] [8] [9] [10] [11] Because of the invasive nature of lumbar puncture in the collection of CSF, neuroimaging modalities such as 18 F-FDG PET and 11 C-PIB PET are more accepted in routine clinical practice to improve the diagnosis of dementia subtype.
The most common functional neuroimaging is with 18 F-FDG 12 and the most common pathological neuroimaging is with 11 C-PIB. 13 These molecular imaging markers are imaged using PET. The 18 F-FDG measures metabolic activity of the brain; 18 F-FDG PET distinguishes well between AD and non-AD dementia. 11 In a systematic review, the sensitivity and specificity for 18 F-FDG PET in distinguishing between AD and DLB was 83%-99% and 71%-93%, respectively; and the sensitivity and specificity for 18 F-FDG PET in distinguishing between AD and FTD was 97.6%-99% and 65%-86%, respectively. 11 In the same systematic review, 18 F-FDG PET predicted patients with mild cognitive impairment (MCI) deteriorating into dementia with sensitivity and specificity of 81%-82% and 86%-90%, respectively. 11 Besides, 11 C-PIB can detect the presence of fibrillar amyloid plaques that are a neuropathological marker of AD. 13 Correlation studies with neuropathology have shown a sensitivity of 90% and specificity of 100%; 11 C-PIB can reasonably distinguish AD from other types of dementia, eg FTD. 13 Using neuropathology as the gold standard, the sensitivity and specificity was 89% and 83%, respectively. 13 The presence of 11 C-PIB retention also predicts the progression of patients with MCI: 50% progress to AD in 1 year and 80% progress to AD within 3 years. 14 Previous studies with 18 F-FDG and 11 C-PIB PET have focused on highly selected diagnostic groups, and only a few studies have studied their impact in the routine clinical setting of a memory clinic at a tertiary university hospital. The latter are referral centres, and often encounter patients with complicated diagnostic issues. Ossenkoppele et al 15 reported a cohort of 145 patients who underwent 18 F-FDG and 11 C-PIB PET after clinical assessment. Change in clinical diagnosis was required in 23% with the diagnostic confidence increased from a mean of 71% to 87%. Diagnosis remained unchanged in 96% after PET over the next 2 years. 15 In seven patients with MCI and positive amyloid deposition on 11 C-PIB PET, six progressed to AD during follow-up (5 had AD pattern of hypometabolism on 18 F-FDG PET). 15 In a retrospective study of 94 patients with MCI or dementia, Laforce et al 16 showed that 18 F-FDG PET brain scan led to a change in diagnosis in 29% of patients, and reduced the frequency of atypical or unclear diagnoses from 39.4% to 16%.
To the best of our knowledge, there are no published data on the impact of molecular neuroimaging on accuracy of diagnosis of AD or other dementias in the Chinese population. We hypothesised that brain 18 F-FDG with or without 11 C-PIB PET imaging can improve the accuracy of diagnosis of common dementia subtypes in a memory clinic. The objective of this study was to investigate the impact of brain 18 F-FDG with or without 11 C-PIB imaging in improving the accuracy of diagnosis of dementia subtype in a local memory clinic in Hong Kong.
Methods
This was a retrospective study conducted at the 17 Patients with DLB were diagnosed by the McKeith criteria. 4 Behavioural variant (bv) of FTD was diagnosed by revised diagnostic criteria reported by the International bvFTD Criteria Consortium 5 and language variant of FTD was diagnosed by latest published criteria. 6 Patients with VaD were diagnosed according to the criteria of the NINDS-AIREN (National Institute of Neurological Disorders and Stroke/Association Internationale pour la Recherche et l'Enseignement en Neurosciences). 18 In this study, we reviewed the medical records of eligible subjects and collected data including age, sex, education level, Mini-Mental State Examination score, Clinical Dementia Rating scale score, molecular imaging report including the standardised uptake value ratio (SUVR) of 11 C-PIB PET, and the pre-and post-imaging diagnoses. For patients who were diagnosed with MCI, their progression during subsequent follow-up visits was also reviewed.
The need for 18 F-FDG with or without 11 C-PIB PET was determined by the geriatrician who performed the initial clinical assessment. The images were evaluated by a radiologist with more than 10 years of experience in reading PET scans. Dementias were classified using the generally accepted criteria. Patients were fasted for at least 4 hours before the PET. The serum glucose level was measured in all patients. For 18 F-FDG PET, the patient was rested in a dimly lit room with eyes closed for 30 minutes prior to injection of 18 F-FDG via a venous catheter. Another 30 minutes of rest was observed before starting the acquisition. The acquired data were semiquantitatively compared with age-stratified normal controls using three-dimensional stereotactic surface projections. For PIB imaging, acquisition was performed at 5 minutes and 35 minutes after 11 C-PIB injection via a venous catheter, and SUVR images of 11 C-PIB between 5 and 35 minutes were generated. Cerebellar grey matter was chosen as reference tissue. In this study, 11 C-PIB PET scans were rated as positive (PIB + ; if binding occurred in more than one cortical brain region; ie frontal, parietal, temporal, or occipital) or negative (PIB -; if predominantly white matter binding).
The pattern of 18 F-FDG PET hypometabolism that is suggestive of each subtype of dementia is as follows 6, 12, 19 : (1) 
Statistical analyses
Descriptive statistics were used for data analyses. 
Results
A total of 109 patients (56.9% were female) were recruited of whom 102 had dementia and seven had MCI. Both 18 F-FDG and 11 C-PIB PET data were available for 45 (41.3%) patients, and 64 patients underwent 18 F-FDG only. The final diagnosis of the 102 demented patients after neuroimaging is shown in Table 1 .
The accuracy of clinical diagnoses is summarised in Table 2 . Overall, PET scans confirmed the clinical impression in 63.7% of patients, and corrected the diagnosis in 36.3%. Using the result of PET scan as the gold standard, the frequency of accurate initial clinical diagnosis was low for FTD, VaD, and mixed dementia (14.3%, 28.6%, and 0%, respectively). The accuracy of clinical diagnosis for AD and DLB was 81.5% and 44.4%, respectively. After excluding subjects with an initial MCI diagnosis, the agreement between the initial and final post-imaging dementia diagnosis was only fair, with a Cohen's κ of 0.25 (95% confidence interval, 0.05-0.45). Table 3 lists the diagnosis of subjects before and after the availability of 18 F-FDG with or without 11 C-PIB PET neuroimaging. For subjects with a final diagnosis of AD (n=65), 18.5% (n=12) were initially diagnosed with non-AD dementia (including 3 with DLB, 2 with FTD, 4 with VaD, and 3 with other dementia) and subsequently received symptomatic AD therapy (ie ChEIs and/or memantine). For the 21 subjects who underwent PIB PET imaging, 19% (n=4) of those with AD (PIB + ) were initially diagnosed with non-AD dementia. For subjects with an initial diagnosis of AD (n=74), 28.4% (n=21) had a change in diagnosis (including 4 DLB, 6 FTD, 4 VaD, 3 mixed AD plus VaD, and 4 with other dementia). Excluding subjects with DLB and mixed AD plus VaD, 13.7% of all subjects (14 out of 102) had discontinued their previous symptomatic AD therapy. For subjects with a final diagnosis of FTD (n=7), 85.7% (n=6) were initially misdiagnosed as AD. For subjects with a final diagnosis of DLB (n=9), 44.4% (n=4) were misdiagnosed as AD.
Five patients were diagnosed with unclassifiable dementia following neuroimaging, which comprised four females and one male with a mean age of 78 ± 9.4 years. All presented with amnesia. In addition, one patient presented with apraxia and dysexecutive syndrome and another presented with hyperorality. All of them were PIB -. An AD pattern of hypometabolism was present in four patients (2 with hypometabolism in posterior cingulate gyrus and 2 with hypometabolism in temporoparietal lobes). Isolated hypometabolism in the temporal lobes was present in one patient.
The clinical information of the seven amnesic MCI subjects are summarised in Table 4 . None of the three subjects without imaging risk factors for AD deteriorated over a follow-up period of 1 to 5 years. Of the four amnesic MCI subjects with imaging risk factors, two deteriorated into AD over a follow-up period of 5 years.
Discussion
In this study, we showed that 18 F-FDG with or without 11 C-PIB PET clarified and improved the accuracy of dementia diagnosis in 36.3% of patients, and confirmed the initial diagnosis in 63.7%. Using the results of PET scan as the gold standard, the accuracy of clinical diagnosis was low for FTD, VaD, and mixed dementia collectively. On the one hand, 11.7% of patients (ie 12 out of 102) were started on symptomatic AD therapy after the 18 F-FDG with or without 11 C-PIB PET neuroimaging investigations. On the other hand, 13.7% of patients (ie 14 out of 102) discontinued symptomatic AD therapy after 18 F-FDG with or without 11 C-PIB PET because they did not have AD.
We also showed that the accuracy of clinical diagnosis of DLB and FTD was low (44.4% and 14.3%, respectively). This finding was in agreement with a previous study. 20 Both DLB and FTD are commonly misdiagnosed clinically as AD (50% for DLB and 85.7% for FTD). 20 We have previously reported that 100% of our patients with biomarkers that confirmed DLB and FTD presented with memory impairment in our memory clinic. 20 A previous study also reported that 26% of DLB patients were initially misdiagnosed with AD, and 57% of these DLB patients presented with memory impairment. 21 We Neuroleptic sensitivity can present as drowsiness, confusion, abrupt worsening of parkinsonism, postural hypotension, or neuroleptic malignant syndrome. 21 Other clinical features of DLB that need to be observed and tackled include well-formed visual hallucinations, rapid eye movement sleep behavioural disorder, and autonomic symptoms (including postural hypotension, sialorrhoea, and urinary and bowel symptoms). 21 By accurately establishing the diagnosis of DLB, careful observation of classic DLB symptoms may reduce unnecessary investigations. Regarding therapeutic implications, DLB is characterised by far greater cholinergic deficits than AD. Hence, most DLB patients will benefit from ChEIs, and the extent of symptomatic improvement should be monitored after such therapy. 22 Similarly, FTD may be misdiagnosed as AD. The former can also present initially with memory impairment, as illustrated by our FTD patients. There is increasing evidence that elderly patients with FTD often present with memory impairment. 5, 23, 24 In one autopsy study, 64% (n=7) of 11 elderly patients with FTD had anterograde memory loss. 23 Current treatment guidelines do not advise giving ChEIs or memantine treatments to FTD patients. Thus, such medications should be stopped to prevent unnecessary adverse effects. 25 In the past few years, disease-modifying treatments (eg bapineuzumab) have failed to demonstrate their efficacy in clinical trials with AD patients. 26 Detailed post-hoc analyses with AD biomarkers have shown the problem of diagnosing AD in subjects recruited in these studies. Only approximately 80% of these subjects had AD amyloid pathology, according to the presence of amyloid PET scan. 26 Thus, including 11 C-PIB PET to confirm brain amyloid in study inclusion criteria can help ensure recruitment of genuine AD patients to future clinical trials of disease-modifying treatments for AD. 27 Given the minimally invasive nature of 11 C-PIB PET compared with CSF amyloid-beta (Aβ) 42 measurements, 7 it is likely to be a more acceptable choice for patients in clinical trials. At present, there are ongoing clinical trials of AD treatments including secretase inhibitors, Aβ aggregation inhibitors, Aβ and tau immunotherapy. 27 We believe that 11 C-PIB PET will play an important role in these clinical trials.
It is considered that 18 F-FDG and 11 C-PIB PET may detect underlying AD in patients with MCI. 28 In the present study, 50% of MCI patients (ie 2 out of 4) with 18 F-FDG and 11 C-PIB PET imaging findings positive for AD showed deterioration over a followup period of 5 years. Although recommending PET brain imaging in MCI patients is still debatable, we believe that this investigation can help clinicians to better plan future and long-term treatments. In particular, disease-modifying drugs for AD or MCI due to AD may prove to be effective in the coming decade. Finally, in the present study, five patients were diagnosed with unclassifiable dementia. In the four patients with an AD pattern of hypometabolism, AD may still be present as they may have diffuse plaques or amorphous plaques that do not bind well to PIB. Alternatively they may have another type of dementia that requires pathological confirmation, eg argyrophilic grain disease or neurofibrillary tangle-only dementia. 29 We will follow up the remaining patient with isolated hypometabolism in the temporal lobes to see whether additional FTD features develop.
There were several limitations to the present study. This was a retrospective case series and as such we were unable to collect further information such as the pre-imaging or post-imaging confidence of diagnosis. The diagnosis of dementia relied on the clinical diagnostic criteria without pathological confirmation. Therefore, we were also unable to compare the relative accuracy of clinical diagnosis and PET diagnosis with pathological diagnosis. For patients with MCI, some were not followed up for sufficiently long to ascertain whether or not they had deteriorated and developed dementia. Structural imaging (including computed tomography or magnetic resonance imaging) of the brain was not analysed as a separate variable but integrated into the pre-functional imaging clinical diagnoses of dementia subtypes. Our case series is likely to have selection bias as PET imaging is mostly a self-paid service in Hong Kong. The exception is for patients who are retired civil servants or recipients of Comprehensive Social Security Assistance. Demented patients who could not afford PET may differ to the patients selected. Although the PET images were analysed and read by radiologists experienced in PET, the interpretations depended heavily on individual experience and training; also, radiologists were not blinded to clinical information written on the request form. Despite these limitations, our study should be more reflective of day-to-day practice in a memory clinic and how 18 F-FDG with or without 11 C-PIB PET imaging may assist clinical diagnosis.
Conclusions
In this study, 18 F-FDG with or without 11 C-PIB brain imaging improved the accuracy of diagnosis of dementia subtype in 36% of patients with underlying AD, DLB, VaD, and FTD who presented to our memory clinic.
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